Clinical trials: Drug Resistance
Obsessive-compulsive Disorder
Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe OCD
Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder characterized by recurrent distressing thoughts and substantial anxiety, accompanied by repetitive behaviors or mental rituals.
- Trial name
- NCT04882839
- Testing
- psychotherapy assisted psilocybin
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Beersheva Mental Health Center
Epilepsy, Partial
An Observational Study to Assess the Burden of Drug-resistant Partial Epilepsy in Italy
observational, non-interventional study in 120 patients with drug-resistant partial epilepsy, comprising two phases: a 3-month retrospective and a 6-month prospective.
- Trial name
- NCT01332539
- Testing
- no intervention
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Drug Resistant Epilepsy
Real-World Study of Magnetic Resonance-guided Laser Interstitial Thermal Therapy for Drug-resistant Epilepsy
The goal of the real-world study is to evaluate the long-term seizure control outcomes, postoperative complications, long term impact on cognitive, memory function outcomes, quality-of-life measures, and healthcare resource…
- Trial name
- NCT06341075
- Testing
- Magnetic Resonance-guided Laser Interstitial Thermal Therapy (MRgLITT)
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Beijing Tiantan Hospital
Focal Segmental Glomerulosclerosis
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
Liposorber® LA-15 System is a blood purification therapy that selectively removes malignant lipoproteins including low density lipoprotein from circulating blood flow and rapidly reduces the plasma cholesterol level.
- Trial name
- FSGS pediatric (NCT02235857)
- Testing
- LIPOSORBER® LA-15 System
- Where
- 12 sites in United States
- Volunteers
- 35 people
- Sponsor
- Kaneka Medical America LLC
Obesity and Obesity-related Medical Conditions
"F!reF!ghterF!t": Lifestyle Coaching Interventions for Obese Firefighters (FireFit)
Our goal is to explore the effectiveness of 9- month lifestyle medicine based coaching intervention (individual and group coaching) versus control (usual care/ written health instructions).
- Trial name
- FireFit (NCT06890975)
- Testing
- Lifestyle Coaching
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Cambridge Health Alliance
CDKL5 Deficiency Disorder
Efficacy and Safety Evaluation of Hyperthermic Baths in the Treatment of Seizures in CDKL5 Deficiency Disorder
The primary objective of this research is to study the efficacy and safety of hyperthermic baths as adjunctive therapy for reducing the frequency of seizures in CDKL5 deficiency.
- Trial name
- NCT06447675
- Testing
- Hyperthermic Baths
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Xuanwu Hospital, Beijing
Pediatric Acute Myeloblastic Leukemia, Relapsed, Pediatric Acute Lymphoblastic Leukemia, Relapsed
AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia
This study is for patients 2-21 years old who have acute leukemia that has not responded well to chemotherapy and will have a bone marrow transplant. This is a pilot (phase 1) study of AMD3100(also called Plerixafor, Mozobil).
- Trial name
- BMTAMD3100 (NCT01655875)
- Testing
- AMD3100
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Emory University
Epilepsy
Serum Profile of Inflammatory Factors, Immune and Angiogenic in Temporal Lobe Epilepsy
Epilepsy affects 0.7% of the general population and 15-20% of patients develop drug resistance. The temporal lobe epilepsy (TLE) is the most common symptomatic focal epilepsies with a particularly high rate of drug (about 20 to…
- Trial name
- NCT01563627
- Testing
- blood sampling for drug resistance biomarkers, Magnetic Resonance Imaging
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Montpellier
Metastatic Castration Resistant Prostate Cancer
IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer
Dose escalation study to evaluate the safety, tolerability and anti-tumor activity of single agent IMU-935 in patients with progressive, metastatic castration resistant prostate cancer (mCRPC).
- Trial name
- NCT05124795
- Testing
- IMU-935
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Immunic AG
Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
To evaluate the efficacy, safety and tolerability at 8 weeks (2-months), 52 weeks (12-months), and 104 Weeks (24-months) post the start of the following treatment regimens in participants with: Drug Sensitive TB (DS-TB) patients…
- Conditions
- Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR, Tuberculosis
- Trial name
- NCT03338621
- Testing
- Pretomanid, Bedaquiline, Moxifloxacin
- Where
- 26 sites in Brazil, Georgia and 6 more
- Volunteers
- 455 people
- Sponsor
- Global Alliance for TB Drug Development
Endometrial Cancer, Gastric Cancer
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid…
- Conditions
- Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer
- Trial name
- NCT05489211
- Testing
- Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil
- Where
- 96 sites in United States, Canada and 12 more
- Volunteers
- 454 people
- Sponsor
- AstraZeneca
Depressive Disorder, Treatment-Resistant
e-PAT Neuromod Evaluation of Personalized rTMS for Resistant Depression
Although repetitive trans-cranial magnetic stimulation (rTMS) is an effective therapy for resistant depression, it still fail to remit up to 70% of these patients.
- Trial name
- NCT02410421
- Testing
- Functional magnetic resonance imaging used to individualize rTMS protocol using robotic coil positioning
- Sponsor
- University Hospital, Strasbourg, France
Synergy Between Plasmid Inhibitors and Combined Antibiotics
Synergistic Effect of Plasmid Inhibitors and Antimicrobial Drugs Against Clinical MDR-hvKP
1. Screening for MDR-hvKP causing VAP in patients admitted to chest ICU in Assiut University Hospital. 2. In vitro evaluation of the synergistic activity of combined meropenem/levofloxacin with and without kasugamycin against…
- Trial name
- NCT05932355
- Volunteers
- 50 people
- Sponsor
- Assiut University
Sturge-Weber Syndrome
Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome
The purpose of this study is to determine the tolerability and optimal dose of cannabidiol (CBD) as an simultaneous treatment in children and young adults with Sturge-Weber syndrome (SWS) and drug resistant epilepsy.
- Trial name
- NCT02332655
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Anne Comi, MD
Healthy
TRK-700 Drug-Drug Interaction Study With Digoxin and Midazolam
This study comprises 2 cohorts, and in each cohort, the study will be conducted as an open-label add-on study. The purpose of the study is to investigate the pharmacokinetics of each substrate in concomitant administration of a…
- Trial name
- NCT03043248
- Testing
- TRK-700, Digoxin, Midazolam
- Where
- Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Toray Industries, Inc
HIV Infections, Lipodystrophy
Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities
The purpose of this study is to see whether metformin alone, rosiglitazone alone, or metformin and rosiglitazone together will lower insulin levels in the blood and decrease fat in the abdomen or other parts of the body.
- Conditions
- HIV Infections, Lipodystrophy, Hyperinsulinemia
- Trial name
- NCT00015691
- Testing
- Metformin hydrochloride, Rosiglitazone maleate
- Where
- 34 sites in United States
- Volunteers
- 105 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Refractory Epilepsy
Localization of the Reward Positivity to ACC
The exact function of the anterior cingulate cortex (ACC) is one of the largest riddles in cognitive neuroscience and a major challenge in mental health research.
- Trial name
- NCT04684797
- Testing
- Virtual T-maze task
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- University Hospital, Ghent
Anti-Infective Agents, Mobile Applications
A Digital Antimicrobial Stewardship Smartphone Application to Combat AMR: the AB-assistant
Optimal prescribing of antimicrobials is becoming increasingly challenging because of the growing complexity of guidelines and constantly changing distribution of infectious pathogens.
- Conditions
- Anti-Infective Agents, Mobile Applications, Quality Improvement, Antimicrobial Stewardship
- Trial name
- AB-assistant (NCT03793946)
- Testing
- AB-assistant
- Where
- 4 sites in Canada, Netherlands and 2 more
- Volunteers
- 1,080 people
- Sponsor
- Annelies Verbon
Healthy Volunteers
Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)
This is an open-label, non-randomized, fixed-sequence study. Subjects will undergo a rosuvastatin phase and eltrombopag and rosuvastatin phase to identify biomarkers for Breast Cancer Resistance Protein (BCRP).
- Trial name
- BCRPmarker (NCT04542382)
- Testing
- Rosuvastatin, Rosuvastatin (Inhibitor arm), Eltrombopag
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Neoplasms, Non-Hodgkin Lymphoma
Study of TPI 287 in Patients With Advanced Malignancies
Tapestry Pharmaceuticals, Inc. has developed a novel taxane analog, TPI 287. TPI 287 is synthetically manufactured from naturally occurring taxanes extracted from yew starting material.
- Conditions
- Neoplasms, Non-Hodgkin Lymphoma, Hodgkin Disease
- Trial name
- NCT00113724
- Testing
- TPI 287 Injection
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Cortice Biosciences, Inc.